Brexit hasn’t stopped access to key drugs – Deo Debattista

DOI/Pierre Sammut

The Parliamentary Secretary for Consumer Rights, Public Cleansing and Support for the Capital City Deo Debattista, has explains that even with the challenges of Brexit, this hasn’t stopped Malta’s access to new drugs.

Mr Debattista explained that in spite of the problems and disruption which the UK’s withdrawal from the European Union could pose, Malta had seen the introduction of 23 new medical drugs for use in therapy.

He explained that 13 of these point-of-care medicines came in liquid forms which could be administered to patients who have problems swallowing.

Further to the importance of Brexit, Chairperson Professor Anthony Serracino-Inglott of the Malta Medicines Authority explained that his authority was ‘well prepared’ for Brexit and reassured audiences that there would not be instances of being out of stock on medications.

The news came as part of an announcement of price reductions on a number of medicines treating conditions like blood clots, osteoporosis and inflammation.

Reductions at a glance:

Pregabalin for neuropathic pain, reduced by 67%

Eye drops for glaucoma, reduced by 45%

Erectile dysfunction medicines, reduced by 30%

Antithrombotic medicines, down by 10%

The Parliamentary Secretary also explained that 14 generic medicines are now available over the counter at discounts over around 82%.

Emtricitabine and Tenofovir used for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV infection, has now been reduced to €95 for 30 tablets.

The antibiotic Fosfomycin has also been reduced by 50% in price.

DOI/Pierre Sammut

These reductions are understood to have been made in cooperation between the Medicines Intelligence and Access Unit operating inside the Malta Medicines Authority, the Malta Competition and Consumer Affairs Authority and a range of local and international distributors of pharmaceuticals.

Readers can view a full list of the medicine price reductions through the MCCAA website: